Unimark aims at moving the value chain from promoting pharmaceutical substances business to encash revenue from finished formulations. Unimark is engaged in formulation development of solid oral, liquid orals, extended release , injectable formulations through strategic Alliance partners.In 2011, Unimark has filed 2 ANDAs in US, 26 MAAs in Europe, 2 ANDS in Canada. Unimark intends to extend its regulatory filings in Asia and Africa in 2012.